Increased EDD mRNA expression has been identified in post-chemotherapy carboplatinum-resistant serous ovarian cancer compared to post-chemotherapy sensitive carcinomas (Peters et al, 2005); in acquired cisplatin-resistant melanoma cell lines (Györffy et al, 2006); and in secondary brain tumours in acute lymphoblastic leukaemia patients arising following chemotherapy (Edick et al, 2005). The gene discussed is UBR5; the disease is ovarian serous adenocarcinoma.